DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
8.78
+0.15 (1.74%)
At close: Dec 5, 2025, 4:00 PM EST
9.05
+0.27 (3.08%)
After-hours: Dec 5, 2025, 7:19 PM EST
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
457.24M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DMAC News
- 23 days ago - DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights - Business Wire
- 26 days ago - DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
- 4 weeks ago - DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025 - Business Wire
- 2 months ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 3 months ago - DiaMedica Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference - Business Wire
- 4 months ago - DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia - Seeking Alpha